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Purpose. In recent years, endoscopic injection became the procedure of choice for the correction of vesicoureteral reﬂux in the
majority of the centers. Unfortunately, endoscopic treatment is not always successful and sometimes requires more than one trial
to achieve similar results to that of an open reimplantation surgery. Our aim of this study is to evaluate the feasibility and success
rateofopenureteralreimplantationfollowingfailedendoscopicprocedure.PatientsandMethods.During2004–2010,weevaluated
16 patients with persistent vesicoureteral reﬂux (grades II–IV) following failed endoscopic treatment. All patients underwent open
ureteral reimplantation. All patients were followed with an ultrasound 6 weeks following surgery and every 6 months thereafter for
an average of 22 months. Voiding cystography was performed at 3 months after surgery. Results. During unilateral open ureteral
reimplantation, the implanted deposit from previous procedures was either excised, drained, or incorporated into the neotunnel
with the ureter. Vesicoureteral reﬂux was resolved in all patients with 100% success rate. No new hydronephrosis or signs of
obstruction developed in any of the patients. qDMSA renal scan was available in 8 patients showing improvement of function in 5
and stable function in 3, and no new scars were identiﬁed. Conclusions. Open ureteral reimplantation is an excellent choice for the
correction of failed endoscopic treatment in children with vesicoureteral reﬂux.
1.Introduction
Vesicoureteral reﬂux (VUR) is a common occurrence in
the pediatric age group resulting in potentially dangerous
morbidities. In some patients, VUR if left untreated could
result in renal scarring [1], hypertension, and end-stage
kidney failure [2, 3]. In most instances, patients are managed
conservatively by observation or medically with prophylactic
antibiotics. For those patients who require interventional
approach, the focus is given to selecting the best corrective
endoscopic or surgical option. Since its introductions in
1984,manyurologicaldepartmentspreferendoscopictissue-
augmenting material injection procedure for the correction
ofVUR[4].Subureteralinjectionofdextranomer/hyaluronic
acid copolymer (Deﬂux) [5] material has been favored over
other injectable agents because of its safety and eﬃcacy [6,
7]. However, as more long-term follow-up studies emerge,
the results indicate that endoscopic treatment has a lower
success rate and a higher recurrence than open ureteral
reimplantation surgery. Some authors do not recommended
to proceed with Deﬂux treatment, after the procedure has
failed in several attempts, due to lower success rate with each
consequent injection [8]. In the setting of a failed endoscopic
injection, both intravesical and extravesical reimplantation
(IUR and EUR) surgical approaches are used [9, 10]. We
report our experience with open ureteral reimplantation
(OUR)forthecorrectionofunsuccessfulendoscopicimplant
and our evaluation of its viability and success rate when
compared to other minimally invasive procedures.
2. Patients andMethods
During 2004–2008, 16 patients with persistent VUR follow-
ing failed endoscopic treatment underwent open reimplan-
tation and were followed until 2010. During this period, we
performed around 400 endoscopic injections. Demographic2 Advances in Urology
data is summarized in Table 1. There were 8 boys and 8 girls,
the mean age was 3.9 years (range: 2–6 years). In this group,
1 patient had 3 previous endoscopic injections, 7 patients
had 2, and 8 patients had one injection. Mean VUR grade
at presentation and before surgery was III (range II–IV).
Indications for operative treatment rather than con-
servative approach were absolute in all patients, includ-
ing breakthrough infections, new scar development, global
renal function deterioration of the reﬂuxing kidney in two
consecutive qDMSA (quantitative DMSA—method used at
Bnai Zion) scans, and an additional male patient who had
persistent reﬂux to a single functioning kidney.
All patients were evaluated by physical examination,
renal ultrasound, voiding cystourethrogram (VCUG), and
qDMSAscanpriortointervention.AllhadprimaryVURand
no other anatomical malformation or neurological impair-
ment.Inallpatientseithervoidingdysfunctionwasruledout
or behavioral modiﬁcation was encouraged prior to surgery.
The reasons to abort additional endoscopic injection
and to proceed with open correction of VUR were single
functioning kidney, deterioration of renal function in two
consecutive qDMSA scans, laterally located ureteral oriﬁces
with a short intramural tunnel limiting the deposition of the
Deﬂuxmaterialcorrectly,parentalpreferencesaswellaswide
ureteral oriﬁce diameter, which could not be managed with
normal amount of bulking material.
Patients underwent reimplantation according to sur-
geon’s preferences; the various methods used are listed in
Table 1. These surgical procedures are already described
extensively in the medical literature [11]. In 9 patients the
Deﬂux deposit was excised from the ureter, in 4 patients it
wasincorporatedintotheneo-tunnel,andin3patientsitwas
drained using a blade to open the bulk capsule and perform
a suction of its content.
All patients were followed with an ultrasound at 6
weeks following surgery and every 6 months thereafter for
an average of 22 months followup (range 8–36 months).
VCUG was performed at 3 months following surgery and a
qDMSA scan around one year after surgery. In all patients,
we emphasized the need for bladder retraining and the
avoidance of voiding dysfunction postoperatively.
3. Results
All surgeries were performed successfully with no intraop-
erative or postoperative complications. All patients voided
spontaneously following catheter removal. Following dis-
charge, one male patient developed transient fever without
a clear source and was treated conservatively. Six weeks after
surgery, sonographic ultrasound did not demonstrate any
signs of new hydronephrosis; in 6 patients, the postvoid
residual scan was included showing complete emptying of
the bladder. VCUG performed in all patients three months
after the operation showed complete resolution of the
VUR. qDMSA scan available in 8 patients showed improved
function in 5 and stable function in 3. No new scars were
detectedinthefollow-upscans.Inameanfollowupof4years
(2–6years),allpatients weredeveloping wellwithserial renal
ultrasoundsshowingappropriaterenalgrowthinallpatients.
4. Discussion
VUR is not uncommon in childhood with a reported
frequency of around 1% [12]. Available treatment options
depend both on the clinical presentation and the grade
of VUR as set forth by the International Reﬂux Study
Classiﬁcation [13]. VCUG is the gold standard in making
the diagnosis [14]. Renal function, clinical presentation, and
VUR grade are essential variables for choosing whether a
conservative or more invasive treatment is the preferred
option for the management of the relevant case.
As minimally invasive procedures become more readily
available, many patients and their parents are ﬁnding them
more appealing and inﬂuential during treatment selection
[15, 16]. From the physician’s view, it is important to
maintain high success rate and provide excellent patient
care, while simultaneously keeping the cost of health care
low. This approach has inﬂuenced doctors to perform
more procedures on an outpatient basis. Such factors have
further contributed to the replacement of open surgery for
endoscopic treatment.
The main advantages of endoscopic treatment for VUR
management include decreased posttreatment pain, bladder
spasm, infection, and absence of surgical scar, especially
in the setting of low grade VUR. The availability of this
procedure in the outpatient setting, short procedure time,
quick time to discharge, and minimal use of postoperative
analgesics have shown to be beneﬁcial for both the patient
and the physician [17]. The ability to repeat this procedure
after initial failure either with implantation or surgery is also
an advantage [10].
More long-term follow-up studies have been published
recently with success rates ranging in the low 80% after one
treatment with Deﬂux, and reaching at best 98% with a
second repeated procedure [18]. Thus, between 10%–20%
of the patients, especially those with VUR grade of III and
higher, will require repeated injections following one treat-
ment with endoscopic implantation [19, 20]. While reﬂux
resolution rates, with the use of Deﬂux, during early postop-
erative followup may seem reasonable (65.9%–80.2%), data
warns of a 1-year total success rate including initial postop-
erative failure of 46.1% [21]. The Hydrodistention Implanta-
tion Technique (HIT) has oﬀered patients up to 90% success
rateforprimaryVURaswellasforcorrectionofrepeatendo-
scopic injection [22]. Nevertheless, both of the aforemen-
tioned procedures still leave a number of patients that will
necessitate repeated corrective procedures. This translates
into additional stress on the patient and the family, further
oﬃce visits, repeated VCUG, more invasive procedures, and
higher costs endured in order to correct the failed treatment.
Endoscopic procedure seems promising with regards to cost,
but careful evaluation of all expenses associated with this
procedure has shown the opposite, that is, the cost for endo-
scopic subureteral injection exceeds that of outpatient open
reimplantation for unilateral vesicoureteral reﬂux [23, 24].
When Deﬂux fails, after the ﬁrst injection, patients are
oﬀered reinjection of Deﬂux or in the case of multiple
failures: surgery. In the open surgery oﬀered for reﬂux,
both IUR and EUR play a crucial role in achieving close toAdvances in Urology 3
Table 1: Patient’s characteristics.
No. Sex Age Side Degree of VUR No. of previous injections Deﬂux globe Type of reimplant
1 M 5 RT 2 1 Incorporated EV
2M 4 R T 3 2 E x c i s e d E V
3M 3 2/12 LT 2 2 Excised EV
4M 3 8/12 LT 4 1 Incorporated EV
5F 2L T 3 1 E x c i s e d E V
6F 2 6/12 RT 3 2 Incorporated EV
7 F 4 LT 2 2 Drained EV
8M 4 B L 3 , 4 2 E x c i s e d P L
9M 6 B L 4 , 4 3 E x c i s e d P L
10 M 4 RT 4 1 Excised PL
11 F 4 BL 2, 3 1 Drained EV
12 F 3 LT 2 2 Drained EV
13 F 4 BL 3, 3 2 Excised Cohen
14 M 5 RT 4 1 Incorporated EV
15 F 3 LT 3 1 Excised EV
16 F 6 BL 2, 3 1 Excised PL
EV: extra vesical
PL: politano leadbetter
100% resolution of VUR. In recent years, both procedures
were modiﬁed to be relatively rapid operations, not always
requiring for the bladder to be opened during the surgery,
ureteral tubing, and for many it is not necessary to leave a
urethral catheter postoperatively. As these techniques are
tailored and advanced, less morbidities such as bladder
spasm, hematuria, and pain, in addition to less use of
postprocedural analgesics are being reported [25–28]. In the
past decade, EUR has become available in the outpatient
settings, thus being comparable to endoscopic treatment
[29]. Both procedures are reported to have relatively short
postoperative stayoflessthan24hours(evenintheinpatient
settings) [30, 31]. When choosing the procedure of choice
for patients with primary VUR, the hospital at which a
patient receives treatment is the one of the most important
features that ensure the selection [32]. While not every
hospital has the ability to perform endoscopic procedure,
most if not all can perform OUR with a high success rate.
Furthermore, evaluation of corrective procedures oﬀered
for VUR after one treatment demonstrates resolution rate
of 98%, 89%, and 78.5% success rates for OUR, HIT, and
endoscopic implant, respectively [8, 22, 23]. These features
m a k eO U Rm o r ea t t r a c t i v ea st h ep r o c e d u r eo fc h o i c ef o r
correction of failed Deﬂux in previous failed trials. We think
it is further justiﬁed to oﬀer OUR for patients who need
maximal success rate including patients with new scars, and
with deteriorating renal function in whom injection failed.
There is a debate whether a routine VCUG is needed
following surgical reimplantation. Falkensammer et al. [33]
retrospectively analyzed results of postoperative VCUG in
126 patients and found that it changed the management
following surgery, in only 2 postoperative studies. The
authors advocated performing VCUG only in patients with
pyelonephritis.Wethinkthatforourpatientswhodeveloped
new scars or had deterioration of renal function prior to
surgery, every eﬀo r ts h o u l db em a d et ov e r i f yt r e a t m e n t
success or failure. In the study mentioned above, 2 patients
developed pyelonephritis postoperatively. This infection can
be devastating for the kidney in young children, especially
those with a previously aﬀected kidney and in patients with
a single kidney. Hence, proper knowledge about residual or
de-novo VUR would enable the physician to prevent it. Since
we decided to give the maximal successful treatment option
to each patient and given that not a lot of data has been pub-
lished in the literature about after failed injection reimplan-
tation, performing VCUG was justiﬁed in our study group.
We performed OUR in an inpatient setting as the
cost of outpatient day surgery is similar to 48 hours
hospitalization in our health care system. In both intravesical
and extravesical approaches, the Deﬂux deposit was excised,
drained, or incorporated into the neo-tunnel, allowing for
minimal scaring and potential complications for the patient
and technical ease for the physician. Keeping the deﬂux
remnant occured only during extravesical reimplantation;
in these cases the surgeon felt that removing the remnant
may compromise the ureter, hence a meticulously tailored
made tunnel capable to include the ureter and the remnant
without any signs of mechanical obstruction was performed.
Fixation of the distal ureter with a U shape suture to the
caudalendoftheneo-tunnelactuallypositionedtheremnant
in the designated place like following a perfect injection.
If the surgeon was not satisﬁed with the results, excision
and either dismembered or intravesical reimplantation were
performed. These patients were constantly followed with
serial ultrasound and none showed any new hydronephrosis.
Even as an inpatient, all patients were discharged within
24–48 hours after EUR. We report 100% long-term success
rate following the correctional repair of failed Deﬂux with
minimal morbidity. Our results are comparative to previous
report.4 Advances in Urology
5. Conclusions
Both intravesical and extravesical techniques are an excellent
choice for the correction of failed endoscopic treatment.
The deﬂux deposit should not alter the surgeon prefer-
able approach to reimplantation. If the Deﬂux deposit is
adhered to the tissue, there is a possibility to excise, drain
or, incorporate it into the neo-tunnel (in EUR) of the
ureter without further complications. Whenever needed, an
immediate high long-term success rate operation following
failed endoscopic injection open reimplantation, regardless
approach, is justiﬁed oﬀering a very high success rate and a
low complication rate.
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